Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by palinc2000on Mar 06, 2024 1:37pm
111 Views
Post# 35918535

RE:Why wasn't 90 a "Major Catalyst"?

RE:Why wasn't 90 a "Major Catalyst"?

Great summary!!
Mind boggling that the exceeding expectations comment has been left out of Press Releases during the last month  or so!
Baxter calling the shots is ludicrous!!! 

Spectral will need to tap the market in a few weeks /months and the fiduciary responsibility of managenent is towards shareholders not Baxter... Keeping the share price down ahead of an Offering does not make sense ...

Are results really exceeding expectations or not!!!
If in fact results are great they need to say so .... If
Baxter  gets frustrated so be it...


hmmmmmmmm wrote:

Shareholders were told for years that the 90/ Interim Enrollment would be a

"major catalyst for the company", but when the PR for 90 came it was the opposite. 

 

 

 

 

Why?

 

 

The "major catalyst" was not about reaching an arbitrary number, it was to be driven by confirmation of positive trial results so far, and proof through the sharing of crude data. 

 

It was the moment for Spectral to proudly reveal their work. To stop saying "we promise", but to show their cards to the market and say- "we told you so..."
 

We are now at 21 days since the 90th patient was enrolled. Next week management could do what they've promised so many times to shareholders - share the crude data and allow the market to react in the positive way they have repeatedly predicted and expect.
 

Since Oct...
 

Feb 5 2024

“enrollment milestone of 90 patients, which is expected to play as a major catalyst for the Company,” said Chris Seto

 

Jan 30 2024

“milestone of 90 patients, which is expected to play as a major catalyst for the Company,” said Chris Seto

 

Jan 10 2024

“enrollment milestone of 90 patients, which is expected to play as a major catalyst for the Company,” said Chris Seto

 

Dec 14 2023

“enrollment milestone of 90 patients, which is expected to play as a major catalyst for the Company,” said Chris Seto

 

Dec 4 2023

“our interim count of 90 patients, which is expected to play as a major catalyst for the Company.” Chris Seto

 

Nov 9 2023

“our interim count of 90 patients, which is expected to play as a major catalyst for the Company,” said Chris Seto

 

Nov 7 2023

“interim count of 90 patients, which is expected to play as a major catalyst for the Company,” said Chris Seto

 

Oct 3 2023

“with a view to enrolling our interim count of 90 patients, which is expected to play as a major catalyst for the Company,” said Chris Seto


 

<< Previous
Bullboard Posts
Next >>